UBT251 FROM NOVO NORDISK! BETTER THAN RETATRUTIDE?
Send a textThis episode unpacks Novo’s aggressive price cuts, Lilly’s head to head trial win, and the emerging triple agonist race, revealing how pricing strategy and next generation data are collidin...
24 Feb 27min
Wegovy vs Zepbound in 2026: New Higher Dose
Send a textWegovy’s new 7.2 mg dose—three times higher than the current max—has just been approved in the EU, with U.S. approval expected soon. But now that Wegovy matches Zepbound on weight loss, the...
17 Feb 20min
Compound Tirzepatide: Time to Stock Up?
Send a textThis week on The Weekly Dose, Dave Knapp breaks down the biggest questions shaking up the GLP-1 world. From whether patients should be stocking up on compounded injectables, to what Eli Lil...
10 Feb 31min
Eli Lilly Earnings Call Q4 2025 Recap
Send a textThis week on On The Pen: The Weekly Dose, Dave breaks down one of the most consequential Eli Lilly earnings calls to date. We dive into major updates on retatrutide, new Phase 3 timelines, ...
4 Feb 21min
Once Monthly GLP-1 Injection? Pfizer Drops New Data
Send a textThis week on On The Pen: The Weekly Dose, we break down Pfizer’s $10 billion bet on obesity medicine and whether it’s shaping up to be a smart move or a costly miss. We dig into newly relea...
3 Feb 21min
PCOS and Tirzepatide Clinical Trial. Finally
Send a textCan Zepbound treat PCOS? That's the question this clinical trial will seek to answer, and we cover it exclusively on this week's On The Pen podcast.Visit TRYSHED.COM to learn more today! Us...
27 Jan 19min
Over The Counter GLP-1 Prediction
Send a textIn this episode of On The Pen: The Weekly Dose, Dave Knapp breaks down why the idea of over-the-counter GLP-1 medications isn’t radical speculation, it’s a pattern already in motion. Drawin...
20 Jan 21min
GLP-1 PLUS Gastric Balloon for added Weight Loss!
Send a textShantanu Gaur, CEO of Allurion, returns to the podcast to break down their swallowable inflatable weight loss balloon, how it works, who it is for, how much it is expected to cost, and when...
19 Jan 31min
